Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

(2016) R. Rampling et al.   CLINICAL CANCER RESEARCH

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

(2016) Brigitta G Baumert et al.   LANCET ONCOLOGY

ATIM-21. IMA950 PEPTIDE-BASED VACCINE ADJUVANTED WITH POLY-ICLC IN COMBINATION WITH STANDARD THERAPY IN NEWLY DIAGNOSED HLA-A2 GLIOBLASTOMA PATIENTS: PRELIMINARY RESULTS

(2016) Denis Migliorini et al.   NEURO-ONCOLOGY

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas

(2016) Ian F. Pollack et al.   NEURO-ONCOLOGY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial

(2015) Renata Ursu et al.   CANCER SCIENCE

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas

(2015) Chul-Kee Park et al.   Oncotarget

Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas

(2014) Ian F. Pollack et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic targets in subependymoma

(2014) Ling-Yuan Kong et al.   JOURNAL OF NEUROIMMUNOLOGY

C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma

(2014) Matthew Parker et al.   NATURE

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Synergy between CD8 T Cells and Th1 or Th2 Polarised CD4 T Cells for Adoptive Immunotherapy of Brain Tumours

(2013) Sabine Hoepner et al.   PLoS One

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

(2012) Valérie Dutoit et al.   BRAIN

Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas

(2011) Feng Wan et al.   BIOMARKERS

Targets for therapy in ependymoma

(2011) Nicole A. Shonka   Targeted Oncology

Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas

(2010) Benito Campos et al.   CANCER SCIENCE

Rapid T cell–based identification of human tumor tissue antigens by automated two-dimensional protein fractionation

(2010) Philipp Beckhove et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

(2010) K. A. Jaeckle et al.   JOURNAL OF NEURO-ONCOLOGY

Ependymal cells: biology and pathology

(2009) Marc R. Del Bigio   ACTA NEUROPATHOLOGICA

Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma

(2009) A. M. Donson et al.   JOURNAL OF IMMUNOLOGY